Skouta, RachidDixon, Scott J.Wang, JianlinDunn, Denise E.Orman, MarinaShimada, KenichiRosenberg, PaulLo, Donald C.Weinberg, Joel M.Linkermann, AndreasStockwell, Brent R.2015-04-012014Skouta, R., S. Dixon, J. Wang, D. E. Dunn, M. Orman, K. Shimada, P. A. Rosenberg, et al. 2014. “Ferrostatins Inhibit Oxidative Lipid Damage and Cell Death in Diverse Disease Models.” Journal of the American Chemical Society 136 (12): 4551-4556. doi:10.1021/ja411006a. http://dx.doi.org/10.1021/ja411006a.0002-7863http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351362Ferrostatin-1 (Fer-1) inhibits ferroptosis, a form of regulated, oxidative, nonapoptotic cell death. We found that Fer-1 inhibited cell death in cellular models of Huntington’s disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction; Fer-1 inhibited lipid peroxidation, but not mitochondrial reactive oxygen species formation or lysosomal membrane permeability. We developed a mechanistic model to explain the activity of Fer-1, which guided the development of ferrostatins with improved properties. These studies suggest numerous therapeutic uses for ferrostatins, and that lipid peroxidation mediates diverse disease phenotypes.en-USArticleJournal Article2015-04-0110.1021/ja411006a